Biopharmaceutical Contract Manufacturing Market Size, Global Trends, And Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Biopharmaceutical Contract Manufacturing Market Size Analysis

Global Biopharmaceutical Contract Manufacturing Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Finished Dosage Form
  1. By Value
3. Active Pharmaceutical Ingredients (APIs)
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Expression System
1. Introduction
  1. Expression System By Value
2. Mammalian
  1. By Value
3. Non-Mammalian
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research (Clinical and Preclinical)
  1. By Value
By Company Size
1. Introduction
  1. Company Size By Value
2. Large and Very Large Companies
  1. By Value
3. Small and Mid-sized Companies
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Finished Dosage Form
  1. By Value
3. Active Pharmaceutical Ingredients (APIs)
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Expression System
1. Introduction
  1. Expression System By Value
2. Mammalian
  1. By Value
3. Non-Mammalian
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research (Clinical and Preclinical)
  1. By Value
By Company Size
1. Introduction
  1. Company Size By Value
2. Large and Very Large Companies
  1. By Value
3. Small and Mid-sized Companies
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Finished Dosage Form
    1. By Value
  3. Active Pharmaceutical Ingredients (APIs)
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Expression System
  1. Introduction
    1. Expression System By Value
  2. Mammalian
    1. By Value
  3. Non-Mammalian
    1. By Value
4. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research (Clinical and Preclinical)
    1. By Value
5. By Company Size
  1. Introduction
    1. Company Size By Value
  2. Large and Very Large Companies
    1. By Value
  3. Small and Mid-sized Companies
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Finished Dosage Form
  1. By Value
3. Active Pharmaceutical Ingredients (APIs)
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Expression System
1. Introduction
  1. Expression System By Value
2. Mammalian
  1. By Value
3. Non-Mammalian
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research (Clinical and Preclinical)
  1. By Value
By Company Size
1. Introduction
  1. Company Size By Value
2. Large and Very Large Companies
  1. By Value
3. Small and Mid-sized Companies
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Finished Dosage Form
    1. By Value
  3. Active Pharmaceutical Ingredients (APIs)
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Expression System
  1. Introduction
    1. Expression System By Value
  2. Mammalian
    1. By Value
  3. Non-Mammalian
    1. By Value
4. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research (Clinical and Preclinical)
    1. By Value
5. By Company Size
  1. Introduction
    1. Company Size By Value
  2. Large and Very Large Companies
    1. By Value
  3. Small and Mid-sized Companies
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Finished Dosage Form
  1. By Value
3. Active Pharmaceutical Ingredients (APIs)
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Expression System
1. Introduction
  1. Expression System By Value
2. Mammalian
  1. By Value
3. Non-Mammalian
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research (Clinical and Preclinical)
  1. By Value
By Company Size
1. Introduction
  1. Company Size By Value
2. Large and Very Large Companies
  1. By Value
3. Small and Mid-sized Companies
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Finished Dosage Form
    1. By Value
  3. Active Pharmaceutical Ingredients (APIs)
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Expression System
  1. Introduction
    1. Expression System By Value
  2. Mammalian
    1. By Value
  3. Non-Mammalian
    1. By Value
4. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research (Clinical and Preclinical)
    1. By Value
5. By Company Size
  1. Introduction
    1. Company Size By Value
  2. Large and Very Large Companies
    1. By Value
  3. Small and Mid-sized Companies
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Finished Dosage Form
  1. By Value
3. Active Pharmaceutical Ingredients (APIs)
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Expression System
1. Introduction
  1. Expression System By Value
2. Mammalian
  1. By Value
3. Non-Mammalian
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research (Clinical and Preclinical)
  1. By Value
By Company Size
1. Introduction
  1. Company Size By Value
2. Large and Very Large Companies
  1. By Value
3. Small and Mid-sized Companies
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Finished Dosage Form
    1. By Value
  3. Active Pharmaceutical Ingredients (APIs)
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Expression System
  1. Introduction
    1. Expression System By Value
  2. Mammalian
    1. By Value
  3. Non-Mammalian
    1. By Value
4. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research (Clinical and Preclinical)
    1. By Value
5. By Company Size
  1. Introduction
    1. Company Size By Value
  2. Large and Very Large Companies
    1. By Value
  3. Small and Mid-sized Companies
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Finished Dosage Form
  1. By Value
3. Active Pharmaceutical Ingredients (APIs)
  1. By Value
By Biologics
1. Introduction
  1. Biologics By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Vaccines
  1. By Value
4. Others
  1. By Value
By Expression System
1. Introduction
  1. Expression System By Value
2. Mammalian
  1. By Value
3. Non-Mammalian
  1. By Value
By Scale of Operation
1. Introduction
  1. Scale of Operation By Value
2. Commercial
  1. By Value
3. Research (Clinical and Preclinical)
  1. By Value
By Company Size
1. Introduction
  1. Company Size By Value
2. Large and Very Large Companies
  1. By Value
3. Small and Mid-sized Companies
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Finished Dosage Form
    1. By Value
  3. Active Pharmaceutical Ingredients (APIs)
    1. By Value
2. By Biologics
  1. Introduction
    1. Biologics By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Vaccines
    1. By Value
  4. Others
    1. By Value
3. By Expression System
  1. Introduction
    1. Expression System By Value
  2. Mammalian
    1. By Value
  3. Non-Mammalian
    1. By Value
4. By Scale of Operation
  1. Introduction
    1. Scale of Operation By Value
  2. Commercial
    1. By Value
  3. Research (Clinical and Preclinical)
    1. By Value
5. By Company Size
  1. Introduction
    1. Company Size By Value
  2. Large and Very Large Companies
    1. By Value
  3. Small and Mid-sized Companies
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Biopharmaceutical Contract Manufacturing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Merck KGAA
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
AGC Biologics
Catalent
FUJIFILM
Patheon
Piramal Pharma Solutions
Pfizer
Serum Institute of India
WuXi Biologics
Samsung BioLogics
Thermo Fisher Scientific Inc.
AbbVie Inc.
Emergent BioSolutions
Biocon
BioCina
Ajinomoto
Albany Molecular Research Inc.
Asymchem
Cobra Biologics
Charles River Laboratories
Goodwin Biotechnology
KBI Biopharma

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment